Antitumor effect of dipyridamole mediated by inhibiting the interaction between platelets and tumor cells Authors: Jie Xue, Jianzhao Deng, Hongwei Qin, Ying Li, Zhongcui Jing, Zhen Zhao, Haiyan Wang Published: 2026 ABSTRACT AbstractDipyridamole is a well-known antithrombotic and a vasodilator. It is used to treat cerebrovascular and cardiovascular diseases owing to its antiplatelet effects. Platelets play a key role in thrombosis and hemostasis, and after cancer cells enter the bloodstream, they interact with these cells to protect them and promote metastasis. Dipyridamole inhibits tumor progression by blocking platelet aggregation and platelet-mediated Epithelial-to-mesenchymal transition (EMT) via targeting the extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinases (MAPK) signaling pathway, further highlighting its potential antitumor properties. However, studies on the anti-tumor mechanisms of dipyridamole are currently limited and incomplete. In this review, we summarize the pathways through which dipyridamole disrupts platelet-tumor cell interactions and exerts antitumor effects, aiming to inform the development of novel anticancer therapies.Keywords: Dipyridamole, Platelet, Cancer, EMT, Blood microenvironment Introduction Dipyridamole possesses diverse pharmacological properties and is commonly used to prevent secondary stroke and transient ischemic attacks because of its vasodilatory and antiplatelet properties [1, 2]. Dipyridamole, a pyrimidopyrimidine derivative, inhibits extracellular adenosine uptake by blocking nucleoside transporters on the plasma membrane [3, 4]. Dipyridamole functions as an inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 5 (PDE5) [5–7]. PDE5, predominantly expressed in platelets, vascular smooth muscle, the heart, brain, lungs, skeletal muscle, and kidney. PDE3 and PDE5 play a key role in regulating platelet aggregation [8–11]. The interaction between tumor cells and platelets facilitates tumor metastasis and enhances survival in the bloodstream [12, 13]. Malignant tumor cells invade the basement membrane and matrix, enter the bloodstream, and associate with leukocytes and platelets to form circulating tumor complexes [14]. The interaction between platelets and circulating tumor cells (CTCs) results in the formation of tumor microemboli, which adhere to endothelial cells and may obstruct distant organs [15, 16]. Tumor metastasis is a multistep process involving reduced cell adhesion, basement membrane degradation, intravasation, immune evasion, and distant organ colonization [17]. Epithelial-to-mesenchymal transition (EMT), a hallmark of primary tumor formation and metastasis, involves the loss of epithelial characteristics and acquisition of mesenchymal traits. Beyond cancer, EMT also plays an essential role in embryonic development and wound healing [18, 19]. EMT reduces primary tumor cell adhesion and promotes infiltration into the bloodstream, resulting in dissemination to distant tissues and contributing significantly to tumor progression [19]. Platelets are key promoters of EMT in the blood circulation [20, 21]. The interaction between tumor cells and activated platelets establishes a pre-metastatic niche, inducing platelet reprogramming and facilitating EMT [20, 21]. Dipyridamole may impede tumor progression by disrupting the interaction between platelets and tumor cells. Nevertheless, the precise mechanisms underlying its antitumor effects remain to be fully elucidated. Platelets and tumors Tumor cells disseminated from the primary lesion can colonize and proliferate at distant sites, and platelets are indispensable during this metastatic transport process. Numerous studies have characterized a variety of molecular mechanisms implicated in platele-driven tumor metastasis. Platelets play several roles in promoting primary tumor growth and dissemination: they regulate the tumor microenvironment, protect CTCs in the vasculature, release platelet-related factors, induce EMT in cancer cells, and promote cancer cell arrest in the bloodstream [22, 23]. Platelets protect CTCs in the vasculature CTCs can induce platelet activation and aggregation after contact with platelets [24, 25]. Platelets can form a physical shield around tumor cells to protect them from cytolysis mediated by natural killer cells in circulation [26]. Platelets interact with CTCs to form tumor microemboli, which obstruct distant organs, facilitate interactions with endothelial cells, and thereby promote tumor metastasis and colonization [15, 27]. Additionally, platelets promote primary tumor cell-related angiogenesis and assist CTCs to disseminate through the bloodstream to distant tissues (Fig. 1) [12, 28]. Platelets are essential components in the tumor microenvironment. Platelets bind to and protect circulating tumor cells from hemodynamic forces and immune cells while they travel in the bloodstream. Platelets can assist circulating tumor cells in spreading to distant tissues via the bloodstream and promote angiogenesis associated with primary tumor cells Platelet-mediated EMT EMT Tumor progression and malignant transformation trigger various EMT-like events that endow primary cancer cells with invasive and metastatic properties [29–31]. EMT involves three major steps: loss of epithelial polarity, loss of cell–cell adhesion, and acquisition of mesenchymal migratory properties (Fig. 2) [32–34]. It is integral to various tumor-related processes, including tumor initiation, the acquisition of stem-like properties, tumor cell migration, invasion into the bloodstream, and resistance to therapy [35–39]. One of the primary triggering events of EMT is the activation of EMT transcription factors (EMT-TFs), such as twist-related protein 1 (Twist1), Snail1, zinc finger E-box binding homeobox 1 (ZEB1), and ZEB2. EMT-TFs typically regulate the expression of each other and cooperate with other TFs to regulate the expression of target genes. EMT-TFs typically act as activators of mesenchymal genes while repressing epithelial genes [39–41]. The EMT process involves three steps: loss of cell–cell adhesion, loss of apical-basal polarity, become invasive mesenchymal cells. EMT generally results in decreased expression of epithelial genes, such as E-cadherin, claudin occludin, Zo-1, Muc1. EMT promotes increased expression of mesenchymal genes, for example, N-cadherin, Vimentin, fibronectin, FSP-1, Β-catenin EMT results in decreased expression of epithelial genes, such as occludin, ZO-1, and E-cadherin. In contrast, EMT activates mesenchymal genes, such as vimentin, N-cadherin, and fibronectin [42]. The downregulation of E-cadherin weakens cell–cell adhesion [43], initiating epithelial dissociation and intercellular junction disassembly. Furthermore, cells undergo major cytoskeletal reorganization, including the upregulation of vimentin and downregulation of keratins, which promote the highly migratory behavior of dissociated cells [44]. The primary function of N-cadherin is to mediate neuronal adhesion. Except in neural cells, the expression level of N-cadherin remains relatively low in other normal cell types. High N-cadherin expression in patients with cancer is positively correlated with poor prognosis [45–47]. As a mesenchymal marker of EMT, N-cadherin is strongly implicated in enhancing tumor invasiveness and metastatic potential [48, 49]. E-cadherin downregulation during EMT is mediated by transcriptional repression via the binding of EMT-TFs to E-boxes, DNA motifs recognized by transcription repressors such as Snail and ZEB1, in the E-cadherin promoter [50]. Aberrant E-cadherin expression is associated with tumor invasion and progression in various cancers, including liver, breast, colorectal, and lung cancers [51–53]. Vimentin, a key intermediate filament (IF) protein, is essential for mesenchymal cell plasticity and promotes post-EMT tumor cell migration [54]. Vimentin is overexpressed in many epithelial cancers, such as breast cancer, malignant melanoma, prostate cancer, gastrointestinal tumors, and lung cancer [54–58]. Platelet-derived growth factor Platelet-derived growth factor (PDGF), released by the alpha granules of platelets, is a vital EMT driver that promotes tumor invasion [59, 60]. PDGF contains four types of chain proteins: PDGF-A, -B, -C, and -D [61]. These four chain proteins can form five functional homodimers or heterodimers: PDGF-AA, -BB, -AB, -CC, and -DD [59]. PDGF promotes EMT in various cancers, including breast, prostate, and pancreatic cancers [62, 63]. PDGF-D promotes tumor cell growth and metastasis by protecting tumor cells from apoptosis through Akt activation, activating tumor cell proliferation through the ERK1/2 and p38 mitogen-activated protein kinase (MAPK) pathways, and promoting tumor cell metastasis via the SDF-1a/CXCR4 pathway [64, 65]. In cholangiocarcinoma, PDGF promotes invasion and metastasis by inducing EMT through the p38/MAPK signaling pathway and by upregulating MMP2/MMP9 expression [66]. In colorectal cancer, PDGF-D promotes tumor growth and metastasis by inducing EMT via activation of the Notch1/Twist1 pathway [67]. In tongue squamous cell carcinoma (TSCC), the PDGF-D/PDGFRB axis triggers the EMT process and participates in tumor cell invasion by activating the p38/AKT/ERK/EMT signaling pathway [65]. PDGF-BB/PDGFR-β can alter PI3K/AKT/mTOR-driven aerobic glycolysis in Wilms’ tumor G401 cells to promote EMT [68]. Transforming growth factor-β The transforming growth factor-β (TGF-β) superfamily consists of both homodimers and heterodimers, including TGF-β isoforms, activin, bone morphogenetic protein (BMP), and Nodal [69]. Platelet alpha granules are particularly enriched in TGF-β1, which is the most abundant and biologically active isoform of the TGF-β superfamily [70, 71]. TGF-β, a potent inducer of EMT, has been extensively studied [72, 73]. Both TGF-β and BMP signaling can activate the ERK, JNK, and p38 MAPK pathways and stimulate the PI3K-Akt-mTOR cascade through the activation of PI3K and Akt, thereby contributing to the TGF-β-mediated EMT response [74]. TGF-β can promote the recruitment of ShcA to the tyrosine-phosphorylated TbRI or TbRII via interaction with its phosphotyrosine-binding (PTB) and Src homology 2 (SH2) domains, thereby initiating ERK signaling [75, 76]. Ligand-bound TGF-β receptors and/or receptor tyrosine kinases (RTKs) can activate non-SMAD signal pathway, which contribute to EMT through non-transcriptional mechanisms [77]. Lysophosphatidic acid Lysophosphatidic acid (LPA) is an important bioactive lipid [78]. The production of LPA and autotaxin contributes to the formation of a tumor-promoting microenvironment that facilitates tumor cell invasion and angiogenesis, thereby supporting cancer progression [79]. LPA is produced by aggregated platelets during tumor cell-induced platelet aggregation [80]. LPA exerts its effects through six G protein-coupled receptors (LPAR1-6), mediating diverse cellular functions, including cell differentiation, cytoskeletal rearrangement, cytokine secretion, and cell motility [81]. In gastric cancer, LPA binds to LPAR2 and activates the Notch signaling pathway, thereby inducing EMT [82]. In ovarian tumors, LPA initiates EMT by integrin-β1-dependent activation of Wnt/β-catenin signaling [83]. In diabetic nephropathy, LPA induces the activation of ERK, JNK, and PI3K/AKT signaling through LPAR1, thereby increasing KLF5 expression and inducing EMT [84]. Briefly, platelets can provide pro-angiogenic and pro-oncogenic factors for CTCs, which are released after platelet activation. Factors released after platelet activation (TGF-β, PDGF, PMPs, and LPA) can induce EMT through the NF-κB, PI3K/Akt, TGF-β/Smad, ERK/MAPK, and Wnt/β-catenin signaling pathways (Fig. 3) [85–88]. After platelet activation, alpha granules release platelet-derived factors such as PDGF, TGF-β, and LPA. Platelet-related factors combine with corresponding receptors to promote EMT transcription program through different signal pathways Tumor cell angiogenesis and extravasation Platelets can promote tumor cell angiogenesis and extravasation. Angiogenesis is a crucial step in tumor occurrence and metastasis. The interaction between CTCs and platelets can induce platelet release vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) [15, 89–93]. VEGF and bFGF promote angiogenesis in distant metastatic tumors [15, 94, 95]. For CTCs to extravasate, they must first disrupt the endothelial barrier. Matrix metalloproteinases (MMPs) facilitate this process by degrading components of the ECM, thereby enhancing vascular permeability. The interaction between CTCs, platelets, and endothelial cells promotes the release of MMPs, aiding in tumor cell extravasation [96, 97]. Platelet-related PDGF and LPA contribute to MMP production [63, 66, 89, 98, 99]. Overall, both angiogenesis and tumor extravasation are closely linked to platelet activity and abundance. However, the interaction between platelets and tumors can be influenced by distinct metastatic microenvironmental factors, such as hypoxia and extracellular matrix components. Antiplatelet monotherapy is associated with an elevated risk of bleeding complications [100]. Therefore, antitumor therapy targeting platelets still warrants cautious consideration. Dipyridamole and platelets Dipyridamole is a vasodilator and an antithrombotic agent [101]. Its mechanism of action mainly involves the following aspects. First, dipyridamole inhibits PDEs, leading to increased levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels in endothelial and smooth muscle cells. cGMP promotes smooth muscle cell relaxation, while both cAMP and cGMP activate protein kinase A (PKA) and protein kinase G (PKG), respectively. These kinases phosphorylate the transcription factor cAMP response element-binding protein (CREB) [102, 103]. Phosphorylated CREB (pCREB) subsequently regulates the expression of different genes involved in cellular metabolism, survival, differentiation, and proliferation. cAMP stimulates the production of prostacyclin (PGI2) in endothelial cells, thereby promoting vascular wall smooth muscle cell relaxation. Second, dipyridamole inhibits erythrocyte uptake of adenosine and increases adenosine levels in the extracellular fluid. Adenosine is an important platelet activation inhibitor. Adenosine binds to its receptor, further stimulating platelet adenyl cyclase and increasing intracellular cAMP levels. Adenosine is rapidly transported into erythrocytes through an equilibrated nucleoside transporter (ENT), which prevents adenosine from interacting with platelets and vessel wall endothelial cells [6]. Overall, dipyridamole promotes vasodilation and antithrombosis primarily through the above mechanisms. Platelet membrane receptors include glycoproteins IIb-IIIa (GPIIb-IIIa), glycoprotein Ib-IX-V (GPIb-IX-V), and glycoprotein VI (GPVI), which are essential for complete cell adhesion and aggregation [104]. Platelet granules include α granules, lysosomal granules, and dense granules. α granules, which are composed of soluble and membrane-bound proteins, are involved in coagulation, angiogenesis, platelet adhesion, and immune cell recruitment [105]. Meanwhile, the dense granules contain ADP and serotonin, which enhance platelet activation and are involved in platelet aggregation. The lysosomal granules contain proteases and glycosidase [106]. Platelet granules not only lead to the growth of tumor vessels but also prevent tumor hemorrhage by maintaining the integrity of the tumor vasculature [107, 108]. In addition to dipyridamole, several other antiplatelet agents have been identified, including dihydrogeodin, ginsenoside Rg5, extracts of Xanthium strumarium, and Lespedeza cuneata. Dihydrogeodin modulates platelet aggregation through downregulation of calcium signaling, αIIbβ3 integrins, and the MAPK and PI3K/Akt pathways [109]. Ginsenoside Rg5 inhibits platelet aggregation via regulation of the GPVI signaling pathway and ferric chloride-induced thrombosis [110]. Antiplatelet activities of Lespedeza cuneata via pharmacological inhibition of integrin αIIbβ3, MAPK, and PI3K/AKT pathways and attenuation of FeCl3-induced thrombosis in mice [111]. Xanthium strumarium L. exerts potent antiplatelet effects via modulation of the MAPK and PI3K/AKT signaling pathways and inhibition of ferric chloride-induced thrombosis [112]. Although the development of novel antiplatelet agents offers expanded therapeutic options, further investigations are warranted to characterize their adverse effect profiles. Antitumor role of dipyridamole Dipyridamole antitumor action by inhibiting platelet aggregation Dipyridamole increases cAMP and cGMP in endothelial and smooth muscle cells, respectively [102, 103, 113]. Tumor growth may be inhibited by increasing cAMP/cGMP levels in cells [114]. Tumor cells reduce cAMP/cGMP levels by overexpressing PDEs. The cAMP/cGMP signaling pathway has been shown to play a significant role in cancer progression [115]. PDEs regulate these signaling molecules by catalyzing their degradation [116, 117]. Platelets can protect tumor cells from hemodynamic and natural killer cells by aggregating around them [26, 118]. By interfering with platelet aggregation, dipyridamole may compromise this protective mechanism, thereby reducing the survival of CTCs in the bloodstream. Dipyridamole antitumor action by inhibiting platelet-mediated EMT Cancer progression is a multifaceted process involving a cascade of molecular alterations, including ERK pathway activation [119], H-Ras oncogene upregulation [120], increased expression of NADPH oxidase-1 (NOX-1), and elevated levels of reactive oxygen species (ROS) [119, 121]. Additional changes include heightened expression of hypoxia-inducible factor 1α (HIF-1α) [122], specificity protein 1 (SP1) expression [123], tumor necrosis factor-α (TNF-α) expression [124], and aldehyde dehydrogenase (ALDH) activity [125]. Moreover, the expression of matrix metalloproteinases-2 (MMP-2) and MMP-9 is often elevated [126], while E-cadherin expression is typically reduced [127]. The Ras-ERK-NOX ROS pathway plays a key role in the induction and maintenance of cellular carcinogenesis [128]. These molecular and pathway changes play important roles in supporting cancer-associated properties during tumorigenesis [121]. Dipyridamole likely impairs cell movement and metastasis by inhibiting the ERK1/2-MAPK signaling pathway [129]. ERK-MAPKs are a well-characterized subfamily of MAPKs. Research has demonstrated the involvement of ERK1/2-MAPK signaling in regulating cell migration [130, 131]. PDGF, EGF, and FGF can activate ERK signaling via the Ras-Raf-MEK1/2-ERK signaling module [132] (Fig. 4). Activated ERK adjusts focal adhesion turnover and membrane protrusions by phosphorylating myosin light-chain kinase (MLCK), leading to focal adhesion disassembly by activating and phosphorylating calpain. Phosphorylation of focal adhesion kinase (FAK) and paxillin through ERK signaling may adjust focal adhesion dynamics and influence paxillin-FAK interplay [132]. ERK regulates cell movement by phosphorylating FAK, MLCK, or calpain [132]. Dipyridamole inhibits ERK1/2 activation, potentially through the elevation of intracellular cAMP levels. This increase in cAMP may prevent the proliferation of human peritoneal mesothelial cells induced by PDGF and TGF-β [133, 134]. Additionally, dipyridamole inhibits the transient upregulation of wt H-Ras, thereby blocking the increase in ROS and DNA damage caused by ERK-Nox pathway activation in each exposure. The antioxidant activity of dipyridamole may be related to its vasodilatory and antithrombotic properties. Dipyridamole can inhibit the formation of free radicals in platelets, endothelial cells, and leukocytes [135, 136], thereby inhibiting platelet aggregation induced by oxygen-derived free radicals [137, 138]. The antioxidant activity of dipyridamole also plays an important role in directly inhibiting downstream ROS production via the Ras-ERK-NOX signaling pathway in PhIP-initiated carcinogenesis [139–142]. PDGF, FGF and EGF can activate ERK signal through the Ras-Raf-MEK1/2-ERK signaling module. ERK dominates cell movement through phosphorylating FAK, MLCK, or calpain Activated platelets release pro-angiogenic and pro-oncogenic factors that aid CTCs. TGF-β and PDGF, in particular, induce EMT via ERK/MAPK signaling [64, 65]. Conversely, dipyridamole suppresses ERK/MAPK signaling, thereby inhibiting cell migration and metastasis [129, 143]. Given that both TGF-β and PDGF promote EMT via ERK-MAPK signaling [65, 74], so dipyridamole may inhibit platelet-mediated EMT by targeting this signaling axis. Other antitumor effects of dipyridamole Dipyridamole is an effective inhibitor to balance nucleoside transport [144, 145]. This transport system rescues the extracellular nucleosides and nucleobases. This can lead to the repletion of nucleotide pools [146] and is one of the many mechanisms of tumor resistance to antimetabolite drugs [147]. Dipyridamole blocks the salvage pathway by inhibiting nucleoside uptake [148]. Dipyridamole also inhibits prostate cancer by blocking the autophagic flux, which is primarily associated with increased intracellular cAMP levels [149]. Dipyridamole combined with aspirin can enhance anticancer effects [150]. Another molecular mechanism underlying the in vivo therapeutic effect of dipyridamole is damaging myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophage (TAMs) infiltration. In the cancer microenvironment, TAMs and MDSCs can promote the survival, proliferation, and dissemination of tumor cells, as well as angiogenesis and repression of adaptive immunity [151, 152]. Additionally, dipyridamole exhibits antioxidant and anti-inflammatory activities [153] and targets EDI3 [154] and HSP90 [155]. The application of dipyridamole in tumor metastasis Dipyridamole has been reported to inhibit tumor cell migration and metastasis in experimental model [143]. In in vitro cell motility assays, 50–100 μM dipyridamole significantly impaired the migration of 4T1-Luc breast cancer cells in a dose-dependent manner. In vivo, it reduced metastasis in both breast and pancreatic cancer xenografts [143, 156], and, in combination with adriamycin, suppressed lung metastasis of B16 melanoma cells [157]. Its antitumor effects have been widely demonstrated across multiple tumor types [139, 143, 149, 156, 158–160]. Dipyridamole differs from other antineoplastic drugs, such as doxorubicin, 5-fluorouracil (5-FU), methotrexate, trametinib, and raltitrexed, in its antitumor mechanism, clinical application, and risk profile, offering unique advantages (Table 1). Additionally, dipyridamole enhances the cytotoxicity of several antitumor drugs in vitro, including doxorubicin [161], 5-FU [162], NB1011 [163], methotrexate [164], trametinib [158], and raltitrexed [165, 166]. Table 1The comparison between dipyridamole and antitumor drugsDrug nameMain antitumor mechanismClinical applicationMajor side effectsRefs.DipyridamoleInhibit balanced nucleoside transport, impairs autophagic flux, antiplatelet aggregation, damage to MDSCs and TAMs infiltrationPrevent stroke and other vascular diseasesRisk of bleeding, migraines[5, 26, 144, 149, 151, 152, 167, 168]DoxorubicinInduce DNA damage, apoptosis–ROS interplay, senescence inductionAntitumor drugCardiotoxicity, damage to other organs[169–173]5-FUInhibition of thymidylate synthase, anabolic actionsAnti-metabolite, chemotherapy drugMyelotoxicity, fever, mucositis, stomatitis, nausea, vomiting, diarrhea[174–176]MethotrexateRapid polyglutamylation, inhibition of dihydrofolate reductaseChemotherapy drug, rheumatoid arthritis, psoriasisNeurotoxicity,[177, 178]TrametinibInduces cell cycle arrestMEK inhibitorDecreased bilateral visual acuity,[179–182]RaltitrexedInhibit thymidylate synthase, inhibit dihydrofolate reductaseCytotoxic agentDiarrhea, nausea, vomiting, fatigue, neutropenia[183–185] The comparison between dipyridamole and antitumor drugs Conclusion and perspectives Dipyridamole inhibits platelet aggregation and activation by inhibiting PDEs and/or blocking adenosine uptake [5, 6]. Platelets interact with tumor cells to form aggregates, which promote the release of related growth factors and prevent tumor cells from being attacked by immune cells, thus promoting the arrest and survival of tumor cells in the blood circulation [186]. This antiplatelet effect underscores dipyridamole's antitumor properties by disrupting platelet-tumor cell interactions [5]. Metastasis is a major cause of cancer-related death [187, 188], with EMT identified as a key mechanism in this process [189]. Platelets supply TGF-β to circulating cancer cells, facilitating their transition into a more migratory state through EMT, which is essential for the metastasis process [85, 190, 191]. Dipyridamole, an antiplatelet drug used in cerebrovascular and cardiovascular diseases [153], disrupts cell movement and metastasis by inhibiting the ERK1/2-MAPK signaling pathway [129]. In contrast, TGF-β and PDGF released by platelets can promote EMT through the ERK-MAPK signaling pathway. The interplay between chemokines and chemokine receptors in the cancer microenvironment is important for achieving metastatic potential [192, 193]. However, Oral bioavailability of dipyridamole is only 11–44%, and it has a low variable oral absorption rate [194]. The water solubility of dipyridamole is related to PH value, which is easy to dissolve in stomach and difficult to dissolve in intestine, so the water solubility of dipyridamole decreases in patients with less hydrochloric acid secretion [195]. There are also related studies to improve the dissolution of dipyridamole, such as modifying the microenvironment PH around dipyridamole particles/molecules [196, 197], solid dispersion [198], self-emulsifying drug delivery system [199] and so on. The use of dipyridamole may also pose risks, including an increased risk of bleeding [200] and migraine [168]. In summary, the combined use of drugs is expected to be a future trend in cancer treatment [201, 202], offering new directions for the development of anticancer therapies. Recent studies indicate that dipyridamole in combination with other drugs yields better efficacy than dipyridamole alone. In the secondary prevention of stroke, the efficacy of combined dipyridamole and aspirin therapy is twice that of either agent used alone [203]. In addition to its antiplatelet effect, dipyridamole possesses anti-inflammatory, antioxidant, and antiproliferative effects. In future clinical practice, dipyridamole may be used in combination with other agents based on its diverse pharmacological activities to achieve enhanced therapeutic efficacy. The tumor microenvironment is highly complex and variable. Factors such as tumor heterogeneity, the presence of various immune cells, and stromal components may influence the effectiveness of dipyridamole. The study may not account for all the different cellular and molecular factors that could alter the drug’s activity in vivo. The antitumor mechanism of dipyridamole requires further investigation to establish it as a viable therapeutic option. Acknowledgements Not applicable. Abbreviations Phosphodiesterase 3 Phosphodiesterase 5 Epithelial-to-mesenchymal transition Circulating tumor cells Platelet-derived growth factor Transforming growth factor-β Extracellular matrix Phosphodiesterases Extracellular signal-regulated kinase Mitogen-activated protein kinases Cyclic adenosine monophosphate Cyclic guanine monophosphate Protein kinase A Protein kinase G Prostacyclin Thromboxane A2 Glycoprotein Ib-IX-V Glycoprotein IIb-IIIa Glycoprotein VI Non-small cell lung cancers Reactive oxygen species NADPH oxidase-1 Hypoxia-inducible factor 1α Specificity protein 1 Tumor necrosis factor-α Matrix metalloproteinase-2 Epidermal growth factor Fibroblast growth factor Myosin light-chain kinase Focal adhesion kinase Tumor-associated macrophages Myeloid-derived suppressor cells Zinc finger E–box binding homeobox 1 Neural Epithelial EMT transcription factors Twist-related protein 1 Tongue squamous cell carcinoma Bone morphogenetic proteins Lysophosphatidic acid 5-Fluorouracil Endoplasmic reticulum Unfolded protein response Author contributions DJZ conducted a literature search and collection of this review. XJ summarized and wrote this manuscript. QHW, LY, JZC, and ZZ provided technical advice. WHY helped substantively revised it. All the authors have reviewed and agreed to submit this manuscript. Funding This study was supported by the joint project on innovation development of the Shandong Provincial Natural Science Fund (Grant No. ZR2022LSW024) and the Clinical Medicine + X Project of Qingdao University (Grant No. 2020018). Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.